Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (5013)	8/14/2001 12:38:07 PM
From: Biomaven	Respond to of 10280

rkrw, I've always been unclear about whether the script numbers capture sales to hospitals. I suspect they don't, which might explain part of the disconnect. I think your Q3 and Q4 projections seem sensible. On the peds label, I agree that simply having a peds label will not by itself make much difference. However, there is a possibility that the peds label will be stronger than their original label in terms of the efficacy/side effect ratio. If so, this could make a big difference (and perhaps even more of a difference once they get their MDI going and get into DTC advertising for Xopenex). Peter